Leerink Partnrs Forecasts Cencora’s Q3 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Research analysts at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for Cencora in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $3.89 per share for the quarter, up from their prior forecast of $3.87. The consensus estimate for Cencora’s current full-year earnings is $15.32 per share. Leerink Partnrs also issued estimates for Cencora’s FY2025 earnings at $15.52 EPS, FY2026 earnings at $17.17 EPS and FY2027 earnings at $19.01 EPS.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%.

A number of other analysts also recently weighed in on COR. Robert W. Baird boosted their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company raised their price target on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Stock Up 0.7 %

Shares of COR opened at $247.94 on Friday. The business’s 50 day simple moving average is $239.01 and its 200-day simple moving average is $236.57. Cencora has a 1 year low of $214.77 and a 1 year high of $262.26. The stock has a market capitalization of $47.92 billion, a price-to-earnings ratio of 33.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio is presently 29.29%.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock valued at $17,790,912 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

A number of large investors have recently bought and sold shares of the company. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares during the last quarter. Concord Wealth Partners purchased a new stake in Cencora in the third quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new stake in Cencora during the 4th quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC raised its stake in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares during the last quarter. Finally, Kentucky Trust Co acquired a new position in shares of Cencora in the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.